Cerexa is a biopharmaceutical company produces a portfolio of anti-infective therapies for the treatment of life-threatening infections.
Cerexa is a biopharmaceutical company focused on the development of a portfolio of novel anti-infective therapies for the treatment of serious and life-threatening infections. The company’s product portfolio includes Ceftaroline AcetateCeftaroline, an injectable cephalosporin that is used for the treatment of bacterial infections caused by gram-positive and gram-negative pathogens.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 23, 2005 | Series A | $50M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
EGS Healthcare Capital Partners | — | Series A |